These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 17321998)

  • 1. Sustained complete cytogenetic remission in a patient with chronic myeloid leukemia after discontinuation of imatinib mesylate therapy.
    Okabe S; Tauchi T; Ishii Y; Akahane D; Nunoda K; Honda S; Takaku T; Ohyashiki K
    Int J Hematol; 2007 Feb; 85(2):173-4. PubMed ID: 17321998
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment with imatinib mesylate in a case of minor BCR-ABL-positive acute myelogenous leukemia.
    Ito K; Tominaga K; Suzuki T; Jinnai I; Bessho M
    Int J Hematol; 2005 Apr; 81(3):242-5. PubMed ID: 15814335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dose modification of imatinib by monitoring the level of BCR-ABL transcript in chronic myelogenous leukemia.
    Ishikawa I; Kato C; Harigae H; Sugawara T; Tomiya Y; Yamada M; Ishizawa K; Kameoka J; Miyamura K; Sasaki T
    Tohoku J Exp Med; 2006 Dec; 210(4):355-63. PubMed ID: 17146202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Transient benefit only from increasing the imatinib dose in CML patients who do not achieve complete cytogenetic remissions on conventional doses.
    Marin D; Goldman JM; Olavarria E; Apperley JF
    Blood; 2003 Oct; 102(7):2702-3; author reply 2703-4. PubMed ID: 14504074
    [No Abstract]   [Full Text] [Related]  

  • 5. High-dose imatinib improves cytogenetic and molecular remissions in patients with pretreated Philadelphia-positive, BCR-ABL-positive chronic phase chronic myeloid leukemia: first results from the randomized CELSG phase III CML 11 "ISTAHIT" study.
    Petzer AL; Wolf D; Fong D; Lion T; Dyagil I; Masliak Z; Bogdanovic A; Griskevicius L; Lejniece S; Goranov S; Gercheva L; Stojanovic A; Peytchev D; Tzvetkov N; Griniute R; Oucheva R; Ulmer H; Kwakkelstein M; Rancati F; Gastl G
    Haematologica; 2010 Jun; 95(6):908-13. PubMed ID: 20145273
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New drug targets genetic malfunction in chronic myeloid leukemia.
    Am J Health Syst Pharm; 2001 Jul; 58(14):1282. PubMed ID: 11471471
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy of dose escalation of imatinib mesylate in patients with cytogenetic or hematologic resistance.
    Sohn SK; Moon JH; Cho YY; Chae YS; Kim JG; Lee KS; Hong SP; Kim SO
    Leuk Lymphoma; 2007 Aug; 48(8):1659-61. PubMed ID: 17701605
    [No Abstract]   [Full Text] [Related]  

  • 8. Sustained cytogenetic remission induced by imatinib mesylate in a chronic myeloid leukemia patient who had a relapse into lymphoid crisis after allogeneic hematopoietic stem cell transplantation.
    Yujiri T; Sato Y; Tanizawa Y
    Int J Hematol; 2004 Jul; 80(1):67-9. PubMed ID: 15293571
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic myeloid leukemia: where do we go now?
    Cortés JE
    Clin Lymphoma Myeloma; 2009; 9 Suppl 4():S374-5. PubMed ID: 20007105
    [No Abstract]   [Full Text] [Related]  

  • 10. Granulocytic sarcoma giant in chronic myeloid leukemia during imatinib mesylate therapy.
    Rosário Cavalheiro Rde C; Vicari P; Maria Morselli F; Ommati LV; Frazão Rosa Fde O; Rodrigues Oliveira JS
    Am J Hematol; 2006 Jan; 81(1):76-7. PubMed ID: 16369975
    [No Abstract]   [Full Text] [Related]  

  • 11. [Molecular relapse of chronic myeloid leukemia after discontinuation of imatinib mesylate for maintaining complete molecular response for more than 2 years].
    Kiguchi T; Tauchi T; Ohyashiki K
    Rinsho Ketsueki; 2009 Jan; 50(1):52-4. PubMed ID: 19225231
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Successful delivery after planned discontinuation of imatinib in a patient with chronic myeloid leukemia.
    Kobayashi K; Takebayashi C; Miyata S; Narimatsu H; Kami M
    Intern Med; 2009; 48(5):369-71. PubMed ID: 19252364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Introduction of imatinib as first-line therapy for chronic myeloid leukemia in Cuba.
    Morán VP; Baute RG; Facundo JC; Ramírez PH; Núñez AA; Martínez EE; Cabrera OM; Padrón CH; Otero AG; Uría JC; Estrada EE; Díaz RM; Virgil AM; Sánchez KL; Cabeza AH
    MEDICC Rev; 2011 Jan; 13(1):35-40. PubMed ID: 21273957
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is it possible to discontinue imatinib mesylate therapy in Chronic Myeloid Leukemia patients with undetectable BCR/ABL? A case report and a review of the literature.
    Guastafierro S; Falcone U; Celentano M; Coppola M; Ferrara MG; Sica A
    Leuk Res; 2009 Aug; 33(8):1079-81. PubMed ID: 19167064
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Constant BCR-ABL transcript level >or=0.1% (IS) in patients with CML responding to imatinib with complete cytogenetic remission may indicate mutation analysis.
    Poláková KM; Polívková V; Rulcová J; Klamová H; Jurcek T; Dvoráková D; Zácková D; Pospísil Z; Mayer J; Moravcová J
    Exp Hematol; 2010 Jan; 38(1):20-6. PubMed ID: 19837125
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular remission in chronic myeloid leukemia patients with sustained complete cytogenetic remission after imatinib mesylate treatment.
    Colombat M; Fort MP; Chollet C; Marit G; Roche C; Preudhomme C; Reiffers J; Praloran V; Mahon FX
    Haematologica; 2006 Feb; 91(2):162-8. PubMed ID: 16461299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imatinib provides durable molecular and cytogenetic responses in a practical setting for both newly diagnosed and previously treated chronic myelogenous leukemia: a study in nagasaki prefecture, Japan.
    Matsuo E; Miyazaki Y; Tsutsumi C; Inoue Y; Yamasaki R; Hata T; Fukushima T; Tsushima H; Imanishi D; Imaizumi Y; Iwanaga M; Sakai M; Ando K; Sawayama Y; Ogawa D; Kawaguchi Y; Nagai K; Tsukasaki K; Ikeda S; Moriuchi Y; Yoshida S; Honda M; Taguchi J; Onimaru Y; Tsuchiya T; Tawara M; Atogami S; Yamamura M; Soda H; Yoshida Y; Matsuo Y; Nonaka H; Joh T; Takasaki Y; Kawasaki C; Momita S; Jinnai I; Kuriyama K; Tomonaga M
    Int J Hematol; 2007 Feb; 85(2):132-9. PubMed ID: 17321991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imatinib mesylate therapy may overcome the poor prognostic significance of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia.
    Quintas-Cardama A; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Verstovsek S; Rios MB; Hayes K; Glassman A; Bekele BN; Zhou X; Cortes J
    Blood; 2005 Mar; 105(6):2281-6. PubMed ID: 15572595
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Induction chemotherapy and post-remission imatinib therapy for de Novo BCR-ABL-positive AML.
    Lazarevic V; Golovleva I; Nygren I; Wahlin A
    Am J Hematol; 2006 Jun; 81(6):470-1. PubMed ID: 16680752
    [No Abstract]   [Full Text] [Related]  

  • 20. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years.
    Rousselot P; Huguet F; Rea D; Legros L; Cayuela JM; Maarek O; Blanchet O; Marit G; Gluckman E; Reiffers J; Gardembas M; Mahon FX
    Blood; 2007 Jan; 109(1):58-60. PubMed ID: 16973963
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.